Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 22 | 2,540 | 33% |
| 2020 | 16 | 2,052 | 36% |
| 2021 | 24 | 2,383 | 39% |
| 2022 | 25 | 2,531 | 41% |
| 2023 | 20 | 2,676 | 43% |
| 2024 | 25 | 2,622 | 45% |
| 2025 from claims | – | 2,669 2,449–2,823 | 46% |
| 2026 forecast | – | 2,754 2,423–3,178 | 46% |
| 2027 forecast | – | 2,835 2,423–3,378 | 47% |
| 2028 forecast | – | 2,918 2,435–3,573 | 47% |
| 2029 forecast | – | 3,003 2,453–3,766 | 47% |
| 2030 forecast | – | 3,091 2,476–3,961 | 48% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 60% of the cases CMS names in New Jersey; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 76% hospital outpatient, 8% surgery center, 12% office. The share outside the hospital has moved −3 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 75 | 6,108−0.3%/yr | −0.3%/yr | 3.7 | 30% | 6,960 in 2030+2.2%/yr |
| Pennsylvania | 52 | 4,366−2%/yr | −2%/yr | 3.5 | 10% | 4,620 in 2030+0.9%/yr |
| Massachusetts | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.6 | 17% | 3,720 in 2030+2.6%/yr |
| Connecticut | 9 | 999−0.1%/yr | −0.1%/yr | 3.3 | 8% | 1,420 in 2030+6%/yr |
| New Hampshire | 3 | 531−0.4%/yr | −0.4%/yr | 2.5 | 6% | 910 in 2030+9.3%/yr |
| Rhode Island | 6 | 346−0.6%/yr | −0.6%/yr | 4.2 | 0% | 430 in 2030+3.6%/yr |
| Maine | 3 | 290−6%/yr | −6%/yr | 2.0 | 7% | 370 in 2030+4%/yr |
| Vermont | 4 | 193−5.7%/yr | −5.7%/yr | 1.8 | 9% | 360 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 53 | 6,600−1.2%/yr | −1.2%/yr | 6.31.6× | 53% | 5,800 in 2030−2.1%/yr |
| Kidney stone management | 109 | 6,001+1.1%/yr | +1.1%/yr | 5.81.0× | 31% | 7,770 in 2030+4.4%/yr |
| Incontinence, prolapse & sacral neuromodulation | 26 | 1,784−4.1%/yr | −4.1%/yr | 1.70.9× | 9% | 1,880 in 2030+0.9%/yr |
| Prostatectomy & nephrectomy | 9 | 867+0.5%/yr | +0.5%/yr | 0.90.7× | 0% | 1,060 in 2030+3.4%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Hologic Sales And Service leads with 39% of company spending on these surgeons in 2025, +11 pts on 2024.
In 2025, 8 companies reported engagement with New Jersey’s surgeons worth $34K in consulting, speaking, meals and travel tied to these products, about $1,378 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.